AAPL312.66+4.03 (+1.31%) ▲|ABBV254.76-6.31 (-2.42%) ▼|ABT95.63+0.23 (+0.24%) ▲|ACN136.96-0.39 (-0.28%) ▼|ADBE218.07-1.65 (-0.75%) ▼|AMAT592.79-10.25 (-1.70%) ▼|AMD552.05+34.23 (+6.61%) ▲|AMGN366.44-7.71 (-2.06%) ▼|AMT162.11-3.92 (-2.36%) ▼|AMZN244.16+1.49 (+0.61%) ▲|AVGO373.90+13.45 (+3.73%) ▲|AXP356.03+4.07 (+1.16%) ▲|BA234.54+8.05 (+3.55%) ▲|BAC59.90+1.17 (+1.99%) ▲|BKNG181.03-3.53 (-1.91%) ▼|BLK1,011.21+15.48 (+1.55%) ▲|BMY56.70-1.43 (-2.46%) ▼|BNY149.96+3.34 (+2.28%) ▲|BRK-B506.58-1.20 (-0.24%) ▼|C143.86+3.89 (+2.78%) ▲|CAT969.92+6.39 (+0.66%) ▲|CL93.39-1.74 (-1.83%) ▼|CMCSA23.38-0.41 (-1.72%) ▼|COF206.50+1.38 (+0.67%) ▲|COP103.58-1.15 (-1.10%) ▼|COST950.25-1.42 (-0.15%) ▼|CRM165.65-0.46 (-0.28%) ▼|CSCO113.98+1.29 (+1.14%) ▲|CVS102.08-2.64 (-2.52%) ▼|CVX168.10-1.10 (-0.65%) ▼|DE635.24+13.97 (+2.25%) ▲|DHR193.62-4.31 (-2.18%) ▼|DIS97.41-2.09 (-2.10%) ▼|DUK125.97-3.63 (-2.80%) ▼|EMR141.56+2.51 (+1.81%) ▲|FDX309.93-3.07 (-0.98%) ▼|GD376.88+3.34 (+0.89%) ▲|GE378.68+1.63 (+0.43%) ▲|GEV1,152.04+38.93 (+3.50%) ▲|GILD129.61-1.66 (-1.26%) ▼|GM77.85+1.85 (+2.43%) ▲|GOOG364.90+8.72 (+2.45%) ▲|GOOGL366.46+6.55 (+1.82%) ▲|GS1,055.29+34.29 (+3.36%) ▲|HD350.65-7.25 (-2.03%) ▼|HON231.18+1.32 (+0.57%) ▲|IBM299.52+10.00 (+3.45%) ▲|INTC122.20+1.85 (+1.54%) ▲|INTU272.14-3.21 (-1.17%) ▼|ISRG432.83+6.82 (+1.60%) ▲|JNJ259.33-3.71 (-1.41%) ▼|JPM337.72+4.75 (+1.43%) ▲|KO82.96-1.18 (-1.40%) ▼|LIN540.52-6.12 (-1.12%) ▼|LLY1,200.06-13.85 (-1.14%) ▼|LMT538.00-7.91 (-1.45%) ▼|LOW223.78-3.72 (-1.64%) ▼|LRCX350.20-1.21 (-0.34%) ▼|MA533.10-6.29 (-1.17%) ▼|MCD279.50-1.13 (-0.40%) ▼|MDLZ59.17-1.74 (-2.86%) ▼|MDT83.06-0.13 (-0.16%) ▼|META600.29+17.39 (+2.98%) ▲|MMM159.15-1.29 (-0.80%) ▼|MO71.88-0.83 (-1.14%) ▼|MRK126.78-2.78 (-2.15%) ▼|MS222.10+8.17 (+3.82%) ▲|MSFT386.74-3.75 (-0.96%) ▼|MU984.75+9.19 (+0.94%) ▲|NEE87.44-0.90 (-1.02%) ▼|NFLX76.02-1.63 (-2.10%) ▼|NKE43.34-0.75 (-1.70%) ▼|NOW107.93+1.61 (+1.51%) ▲|NVDA195.55+0.72 (+0.37%) ▲|ORCL143.76+3.49 (+2.49%) ▲|PEP143.29-0.93 (-0.64%) ▼|PFE23.72-0.60 (-2.47%) ▼|PG149.31-2.10 (-1.39%) ▼|PLTR132.54+3.24 (+2.51%) ▲|PM184.76+2.49 (+1.37%) ▲|QCOM186.48+10.23 (+5.80%) ▲|RTX201.37+2.12 (+1.06%) ▲|SBUX102.11-2.16 (-2.07%) ▼|SCHW100.62+3.62 (+3.73%) ▲|SO95.99-1.99 (-2.03%) ▼|SPG225.00-1.06 (-0.47%) ▼|T20.58+0.00 (+0.00%) ▲|TMO517.60-5.84 (-1.12%) ▼|TMUS181.79+4.27 (+2.41%) ▲|TSLA419.77+26.32 (+6.69%) ▲|TXN303.50+10.42 (+3.56%) ▲|UBER72.42-2.01 (-2.70%) ▼|UNH417.99-7.37 (-1.73%) ▼|UNP282.59+0.34 (+0.12%) ▲|UPS110.02-0.64 (-0.58%) ▼|USB62.83+1.10 (+1.78%) ▲|V357.25-4.88 (-1.35%) ▼|VZ42.07-0.49 (-1.15%) ▼|WFC87.45+1.94 (+2.27%) ▲|WMT110.65-1.19 (-1.06%) ▼|XOM136.44-0.65 (-0.47%) ▼|AAPL312.66+4.03 (+1.31%) ▲|ABBV254.76-6.31 (-2.42%) ▼|ABT95.63+0.23 (+0.24%) ▲|ACN136.96-0.39 (-0.28%) ▼|ADBE218.07-1.65 (-0.75%) ▼|AMAT592.79-10.25 (-1.70%) ▼|AMD552.05+34.23 (+6.61%) ▲|AMGN366.44-7.71 (-2.06%) ▼|AMT162.11-3.92 (-2.36%) ▼|AMZN244.16+1.49 (+0.61%) ▲|AVGO373.90+13.45 (+3.73%) ▲|AXP356.03+4.07 (+1.16%) ▲|BA234.54+8.05 (+3.55%) ▲|BAC59.90+1.17 (+1.99%) ▲|BKNG181.03-3.53 (-1.91%) ▼|BLK1,011.21+15.48 (+1.55%) ▲|BMY56.70-1.43 (-2.46%) ▼|BNY149.96+3.34 (+2.28%) ▲|BRK-B506.58-1.20 (-0.24%) ▼|C143.86+3.89 (+2.78%) ▲|CAT969.92+6.39 (+0.66%) ▲|CL93.39-1.74 (-1.83%) ▼|CMCSA23.38-0.41 (-1.72%) ▼|COF206.50+1.38 (+0.67%) ▲|COP103.58-1.15 (-1.10%) ▼|COST950.25-1.42 (-0.15%) ▼|CRM165.65-0.46 (-0.28%) ▼|CSCO113.98+1.29 (+1.14%) ▲|CVS102.08-2.64 (-2.52%) ▼|CVX168.10-1.10 (-0.65%) ▼|DE635.24+13.97 (+2.25%) ▲|DHR193.62-4.31 (-2.18%) ▼|DIS97.41-2.09 (-2.10%) ▼|DUK125.97-3.63 (-2.80%) ▼|EMR141.56+2.51 (+1.81%) ▲|FDX309.93-3.07 (-0.98%) ▼|GD376.88+3.34 (+0.89%) ▲|GE378.68+1.63 (+0.43%) ▲|GEV1,152.04+38.93 (+3.50%) ▲|GILD129.61-1.66 (-1.26%) ▼|GM77.85+1.85 (+2.43%) ▲|GOOG364.90+8.72 (+2.45%) ▲|GOOGL366.46+6.55 (+1.82%) ▲|GS1,055.29+34.29 (+3.36%) ▲|HD350.65-7.25 (-2.03%) ▼|HON231.18+1.32 (+0.57%) ▲|IBM299.52+10.00 (+3.45%) ▲|INTC122.20+1.85 (+1.54%) ▲|INTU272.14-3.21 (-1.17%) ▼|ISRG432.83+6.82 (+1.60%) ▲|JNJ259.33-3.71 (-1.41%) ▼|JPM337.72+4.75 (+1.43%) ▲|KO82.96-1.18 (-1.40%) ▼|LIN540.52-6.12 (-1.12%) ▼|LLY1,200.06-13.85 (-1.14%) ▼|LMT538.00-7.91 (-1.45%) ▼|LOW223.78-3.72 (-1.64%) ▼|LRCX350.20-1.21 (-0.34%) ▼|MA533.10-6.29 (-1.17%) ▼|MCD279.50-1.13 (-0.40%) ▼|MDLZ59.17-1.74 (-2.86%) ▼|MDT83.06-0.13 (-0.16%) ▼|META600.29+17.39 (+2.98%) ▲|MMM159.15-1.29 (-0.80%) ▼|MO71.88-0.83 (-1.14%) ▼|MRK126.78-2.78 (-2.15%) ▼|MS222.10+8.17 (+3.82%) ▲|MSFT386.74-3.75 (-0.96%) ▼|MU984.75+9.19 (+0.94%) ▲|NEE87.44-0.90 (-1.02%) ▼|NFLX76.02-1.63 (-2.10%) ▼|NKE43.34-0.75 (-1.70%) ▼|NOW107.93+1.61 (+1.51%) ▲|NVDA195.55+0.72 (+0.37%) ▲|ORCL143.76+3.49 (+2.49%) ▲|PEP143.29-0.93 (-0.64%) ▼|PFE23.72-0.60 (-2.47%) ▼|PG149.31-2.10 (-1.39%) ▼|PLTR132.54+3.24 (+2.51%) ▲|PM184.76+2.49 (+1.37%) ▲|QCOM186.48+10.23 (+5.80%) ▲|RTX201.37+2.12 (+1.06%) ▲|SBUX102.11-2.16 (-2.07%) ▼|SCHW100.62+3.62 (+3.73%) ▲|SO95.99-1.99 (-2.03%) ▼|SPG225.00-1.06 (-0.47%) ▼|T20.58+0.00 (+0.00%) ▲|TMO517.60-5.84 (-1.12%) ▼|TMUS181.79+4.27 (+2.41%) ▲|TSLA419.77+26.32 (+6.69%) ▲|TXN303.50+10.42 (+3.56%) ▲|UBER72.42-2.01 (-2.70%) ▼|UNH417.99-7.37 (-1.73%) ▼|UNP282.59+0.34 (+0.12%) ▲|UPS110.02-0.64 (-0.58%) ▼|USB62.83+1.10 (+1.78%) ▲|V357.25-4.88 (-1.35%) ▼|VZ42.07-0.49 (-1.15%) ▼|WFC87.45+1.94 (+2.27%) ▲|WMT110.65-1.19 (-1.06%) ▼|XOM136.44-0.65 (-0.47%) ▼|

19 C

New York

Tuesday, July 7, 2026

Tineco’s World #1 Floor Cleaner Range Up To 46% Off For Amazon Prime Day

Woven Woven Redefines Children’s Sleep Wellness with Innovative Bead-Free Weighted Blankets

Focusing on On-Chain-Native Prediction Markets: BM Wallet Launches Prediction Markets, Reimagining the Web3 User Experience

Tag: as

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney diseaseZHUBEI CITY, Taiwan and RALEIGH, N.C.,...

Oban BioPharma Announces Presentation of Late-Breaking Abstract at ADA 2026 Highlighting OBT-676: A First-in-Class Small Molecule Combining Dual Amylin and Calcitonin Receptor Full Agonism...

STAMFORD, Conn., June 05, 2026 (GLOBE NEWSWIRE) -- Oban BioPharma today announced that preclinical data for OBT-676, a lead small-molecule candidate for the treatment of obesity and type 2 diabetes, has been selected for a late-breaking presentation at the upcoming American Diabetes Association (ADA) 86th Scientific Sessions being held from June 5^th-8^th in New Orleans, LA. The study characterizes OBT-676 as a new molecular entity that achieves potent full agonism at the amylin and calcitonin receptors (DACRA) while simultaneously delivering partial agonism across the GLP-1, GIP, and glucagon (Triple-G) pathways. OBT-676 demonstrated significant reduction in food intake and adipose-selective weight loss in the industry-standard rat diet-induced obesity (DIO) model.

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Study of Over Three Million Patients for Risk of Type 2 Diabetes Demonstrates Potential for More Advanced Approach to Early IdentificationNEW ORLEANS, June 5,...

Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

NEW YORK, June 5, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, and S&P...

The City of Hallandale Beach Among 10 Finalists for Climate Protection from US Conference of Mayors; Cloud Receives Small City Award

HALLANDALE BEACH, Fla., June 5, 2026 /PRNewswire/ -- The City of Hallandale Beach was recognized as a finalist in the Small City category of...

DNOW Investor News: If You Have Suffered Losses in DNOW Inc. (NYSE: DNOW), You Are Encouraged to Contact The Rosen Law Firm About Your...

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of DNOW Inc. (NYSE: DNOW) resulting from allegations that DNOW Inc. may have issued materially misleading business information to the investing public.

Xsolis, Inc. Provides Notice of Data Security Incident

FRANKLIN, Tenn., June 5, 2026 /PRNewswire/ -- Xsolis, Inc. ("Xsolis"), a vendor that provides case and utilization management services to healthcare organizations, today announced...

Yuno Provides Corporate Update as It Advances Toward Launch, Expands Leadership Team with Talent from Binance, and Positions for Global Prediction Market Growth

Yuno provided a corporate update ahead of launch, highlighting leadership growth, product progress, and global expansion plans.

PFSI Investor News: If You Have Suffered Losses in PennyMac Financial Services, Inc. (NYSE: PFSI), You Are Encouraged to Contact The Rosen Law Firm...

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of PennyMac Financial Services, Inc. (NYSE: PFSI) resulting from allegations that PennyMac may have issued materially misleading business information to the investing public.

HELE Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Helen of Troy Limited. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Helen of Troy Limited (HELE) Misled Investors Regarding the Ability of Project Pegasus to Improve Efficiency

BMI Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in Badger Meter, Inc. Class Action Lawsuit

Robbins LLP is Investigating Allegations that Badger Meter, Inc. (BMI) Concealed Weakening Demand and Deteriorating Near-Term Order Trends

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Phone

This field is for validation purposes and should be left unchanged.

HomeTagsAs